Joint Research Chair

Urological Immuno-oncology

Using omics to find biomarkers for immune checkpoint inhibitors
  • Utility of genomics and proteomics to predict the effect of immune checkpoint inhibitors

Using omics analysis to find biomarkers of the response to immune checkpoint inhibitors

Immunotherapy is now emerging and promising treatment for various types of cancer. Especially, immune checkpoint inhibitors have proven to be an effective form of immunotherapy in these several years. However, roughly only 20-30% of patients benefit from this treatment and several autoimmune side effects have been already recorded. Thus, there is a urgent need for prediction methods that can identify which patients are most likely to benefit from immune checkpoint inhibitors. So far, it is generally accepted that high expression of Programmed Death-Ligand 1 (PD-L1) in tumor tissues is a good indicator of a positive response, but there still remain some issues to be resoloved. To find reliable biomarkers that can be used to predict the response to immune checkpoint inhibitors, we are using novel strategies that include genomics and proteomics analyses.